In an exciting development for mental health treatment, Lupin has introduced a generic version of a medication for schizophrenia and bipolar disorder in the US. This innovative product comes as an extended-release injectable suspension and is backed by a remarkable 180 days of exclusivity. This launch illustrates Lupin's commitment to advancing complex injectable solutions in a growing US market.